Abstract CT084: A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)
Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Robert Zerbib(Inflarx (Germany)), Daniel Castellano(Universidad Complutense de Madrid), Melissa A. Reimers(Washington University in St. Louis), Enrique Grande(MD Anderson Cancer Center Madrid), Andrew Weickhardt(Austin Hospital), Scot A. Niglio(National Cancer Institute), Mehmet Asım Bilen(Emory Healthcare), Guru Sonpavde(AdventHealth Orlando), Stéphane Champiat(The University of Texas MD Anderson Cancer Center), Amita Patnaik(South Texas Accelerated Research Therapeutics), Arjun Vasant Balar(NYU Langone Health), Craig Gedye(Centre for Cancer Biology), Matthew I. Milowsky(UNC Lineberger Comprehensive Cancer Center), Minna Balbas(Roswell Park Comprehensive Cancer Center), Thibault De La Motte Rouge(Inserm), Kaitlyn Aptaker(Loxo Oncology at Lilly (United States)), Armelle Viceneux(Centre Léon Bérard), Tian Zhang(Duke Medical Center), Xīn Gào(Qingdao University), Xiaojian Xu(Loxo Oncology at Lilly (United States)), Loïc Lebellec(Centre Oscar Lambret), Philippe Barthélémy(Institut de Cancérologie Strasbourg), Renaud Sabatier(Centre National de la Recherche Scientifique)
Cited by 9
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k